Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 2 (2005), Issue 2 (February)

1. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery.
   DNA Cell Biol, 23(12): 850-7. [Abstract] [Full-text]
2. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma.
   Mol Cell Biol, 25(4): 1228-37. [Abstract] [Full-text]
3. Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer.
   Eur Respir J, 25(2): 329-35. [Abstract] [Full-text]
4. Repeat needle biopsies combined with clinical observation are safe and accurate in the management of a solitary pulmonary nodule.
   Cancer, 103(3): 599-607. [Abstract] [Full-text]
5. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma.
   Cancer, 103(3): 608-15. [Abstract] [Full-text]
6. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1.
   Cancer, 103(3): 509-15. [Abstract] [Full-text]
7. Early diagnosis of lung cancer by detection of tumor liberated protein.
   J Cell Physiol, 203(1): 1-5. [Abstract] [Full-text]
8. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis.
   Oncogene, 24(6): 1084-90. [Abstract] [Full-text]
9. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia.
   Blood, 105(4): 1797-802. [Abstract] [Full-text]
10. Predictors of prolonged air leak following pulmonary lobectomy.
    Eur J Cardiothorac Surg, 27(2): 334-6. [Abstract] [Full-text]
11. Estimating hospital costs attributable to prolonged air leak in pulmonary lobectomy.
    Eur J Cardiothorac Surg, 27(2): 329-33. [Abstract] [Full-text]
12. Results of pulmonary resection for lung cancer in Norway, patients older than 70 years.
    Eur J Cardiothorac Surg, 27(2): 325-8. [Abstract] [Full-text]
13. Overview of observational studies of low-dose helical computed tomography screening for lung cancer.
    Respirology, 10(1): 97-104. [Abstract] [Full-text]
14. Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value.
    Respirology, 10(1): 31-5. [Abstract] [Full-text]
15. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
    Cancer Immunol Immunother, 54(4): 315-27. [Abstract] [Full-text]
16. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase.
    Cancer Lett, 219(1): 71-81. [Abstract] [Full-text]
17. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
    Histopathology, 46(2): 195-201. [Abstract] [Full-text]
18. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study.
    BMJ, 330(7486): 277. [Abstract] [Full-text]
19. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis.
    Hum Mol Genet, 14(4): 475-82. [Abstract] [Full-text]
20. Evidence for immune defects in breast and lung cancer patients.
    Cancer Immunol Immunother, 53(12): 1146-52. [Abstract] [Full-text]
21. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
    J Cancer Res Clin Oncol, 131(4): 261-9. [Abstract] [Full-text]
22. Non-small-cell lung cancer in a French department, (1982-1997): management and outcome.
    Br J Cancer, 92(3): 459-66. [Abstract] [Full-text]
23. Tumor-associated macrophages: the double-edged sword in cancer progression.
    J Clin Oncol, 23(5): 953-64. [Abstract] [Full-text]
24. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
    Br J Cancer, 92(1): 131-9. [Abstract] [Full-text]
25. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
    Br J Cancer, 92(1): 15-20. [Abstract] [Full-text]
26. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
    Br J Cancer, 92(1): 13-4. [Abstract] [Full-text]
27. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
    Hum Gene Ther, 16(1): 26-34. [Abstract] [Full-text]
28. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Diagn Cytopathol, 32(3): 137-44. [Abstract] [Full-text]
29. Waking the dying: must we always attempt to involve critically ill patients in end-of-life decisions?
    Chest, 127(2): 637-42. [Abstract] [Full-text]
30. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer.
    Chest, 127(2): 449-54. [Abstract] [Full-text]
31. Feasibility of the detection of the sentinel lymph node in peripheral non-small cell lung cancer with radio isotopic and blue dye techniques.
    Chest, 127(2): 443-8. [Abstract] [Full-text]
32. Transesophageal echographic determination of aortic invasion by lung cancer.
    Chest, 127(2): 438-42. [Abstract] [Full-text]
33. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration.
    Chest, 127(2): 430-7. [Abstract] [Full-text]
34. The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest.
    Lancet, 365(9458): 531-40. [Abstract] [Full-text]
35. Gefitinib in advanced non-small cell lung cancer.
    Intern Med J, 35(2): 77-82. [Abstract] [Full-text]
36. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.
    Oncogene, 24(7): 1212-9. [Abstract] [Full-text]
37. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Oncologist, 10(2): 138-49. [Abstract] [Full-text]
38. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer.
    Jpn J Clin Oncol, 35(2): 57-60. [Abstract] [Full-text]
39. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    Int J Radiat Oncol Biol Phys, 61(3): 649-55. [Abstract] [Full-text]
40. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.
    Urology, 65(2): 295-9. [Abstract] [Full-text]
41. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
    Hum Pathol, 36(1): 44-50. [Abstract] [Full-text]
42. Effects of cryotherapy or chemotherapy on apoptosis in a non-small-cell lung cancer xenografted into SCID mice.
    Cryobiology, 50(1): 29-37. [Abstract] [Full-text]
43. Adenosquamous carcinoma of the lung: CT-pathological correlation.
    Clin Radiol, 60(3): 364-9. [Abstract] [Full-text]
44. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line.
    Biochemistry, 44(7): 2253-61. [Abstract] [Full-text]
45. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
    Cancer, 103(4): 772-9. [Abstract] [Full-text]
46. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Cancer, 103(4): 763-71. [Abstract] [Full-text]
47. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population.
    Int J Cancer, 114(3): 455-60. [Abstract] [Full-text]
48. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
    Int J Cancer, 114(3): 400-5. [Abstract] [Full-text]
49. Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility.
    Int J Cancer, 114(3): 394-9. [Abstract] [Full-text]
50. hOGG1 Ser326Cys polymorphism and G:C-to-T:A mutations: no evidence for a role in tobacco-related non small cell lung cancer.
    Int J Cancer, 114(3): 387-93. [Abstract] [Full-text]
51. Paraneoplastic limbic encephalitis--case report and review of literature.
    Age Ageing, 34(2): 190-3. [Abstract] [Full-text]
52. An overview of lung cancer genomics and proteomics.
    Am J Respir Cell Mol Biol, 32(3): 169-76. [Abstract] [Full-text]
53. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
    Lung Cancer, 47(3): 421-3. [Abstract] [Full-text]
54. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
    Lung Cancer, 47(3): 413-9. [Abstract] [Full-text]
55. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
    Lung Cancer, 47(3): 405-12. [Abstract] [Full-text]
56. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
    Lung Cancer, 47(3): 395-404. [Abstract] [Full-text]
57. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
    Lung Cancer, 47(3): 385-94. [Abstract] [Full-text]
58. A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated.
    Lung Cancer, 47(3): 373-80. [Abstract] [Full-text]
59. Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients.
    Lung Cancer, 47(3): 361-71. [Abstract] [Full-text]
60. Prognostic value of smoking status in operated non-small cell lung cancer.
    Lung Cancer, 47(3): 351-9. [Abstract] [Full-text]
61. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC).
    Lung Cancer, 47(3): 337-50. [Abstract] [Full-text]
62. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?
    Lung Cancer, 47(3): 325-36. [Abstract] [Full-text]
63. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.
    Lung Cancer, 47(3): 315-23. [Abstract] [Full-text]
64. Aberrant methylation of Reprimo in lung cancer.
    Lung Cancer, 47(3): 309-14. [Abstract] [Full-text]
65. Familial multiple primary lung cancers: a population-based analysis from Sweden.
    Lung Cancer, 47(3): 301-7. [Abstract] [Full-text]
66. Psychosocial aspects of lung cancer.
    Lung Cancer, 47(3): 293-300. [Abstract] [Full-text]
67. Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity.
    Exp Mol Pathol, 78(2): 135-9. [Abstract] [Full-text]
68. Carcinogen specific dosimetry model for passive smokers of various ages.
    Sci Total Environ, 338(3): 201-12. [Abstract] [Full-text]
69. Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells.
    Am J Respir Cell Mol Biol, 32(3): 211-7. [Abstract] [Full-text]
70. Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers.
    Mol Carcinog, 42(3): 150-8. [Abstract] [Full-text]
71. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids.
    Am J Clin Pathol, 123(3): 394-404. [Abstract] [Full-text]
72. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC).
    Oncogene, 24(8): 1412-22. [Abstract] [Full-text]
73. Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations.
    Cancer, 105(1): 35-43. [Abstract] [Full-text]
74. Cytologic factors associated with prognosis in patients with peripheral adenocarcinoma of the lung measuring 3 cm or less in greatest dimension.
    Cancer, 105(1): 44-51. [Abstract] [Full-text]
75. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications.
    Mod Pathol, 18(3): 320-3. [Abstract] [Full-text]
76. PDGF-A, PDGF-Rbeta, TGFbeta3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study.
    Mod Pathol, 18(3): 382-7. [Abstract] [Full-text]
77. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    J Neurooncol, 71(1): 61-5. [Abstract] [Full-text]
78. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk.
    Am J Epidemiol, 161(5): 412-22. [Abstract] [Full-text]
79. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
    J Clin Oncol, 23(6): 1144-51. [Abstract] [Full-text]
80. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
    J Clin Oncol, 23(6): 1136-43. [Abstract] [Full-text]
81. Molecular prognostic factors in resectable non-small cell lung cancer.
    Crit Rev Oncol Hematol, 53(3): 193-7. [Abstract] [Full-text]
82. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
    J Clin Oncol, 23(6): 1061-9. [Abstract] [Full-text]
83. Assessment of Tc-99m sestamibi tumor tissue uptake under the influence of increased arterial oxygen saturation.
    Nucl Med Biol, 32(2): 165-70. [Abstract] [Full-text]
84. False-positive reduction in computer-aided diagnostic scheme for detecting nodules in chest radiographs by means of massive training artificial neural network.
    Acad Radiol, 12(2): 191-201. [Abstract] [Full-text]
85. Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe.
    Neoplasia, 6(6): 802-12. [Abstract] [Full-text]
86. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.
    Neoplasia, 6(6): 777-85. [Abstract] [Full-text]
87. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection.
    Neoplasia, 6(6): 761-7. [Abstract] [Full-text]
88. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
    Neoplasia, 6(6): 736-43. [Abstract] [Full-text]
89. Evaluation of toxic agent effects on lung cells by fiber evanescent wave spectroscopy.
    Appl Spectrosc, 59(1): 1-9. [Abstract] [Full-text]
90. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
    BMC Cancer, 5(1): 15. [Abstract] [Full-text]
91. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Ann Oncol, 16(3): 425-9. [Abstract] [Full-text]
92. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.
    Ann Oncol, 16(3): 430-6. [Abstract] [Full-text]
93. Lung cancer in smoking patients inversely alters the activity of hOGG1 and hNTH1.
    Cancer Lett, 219(2): 191-5. [Abstract] [Full-text]
94. Mycobacterium tuberculosis infection and FHIT gene alterations in lung cancer.
    Cancer Lett, 219(2): 155-62. [Abstract] [Full-text]
95. Lung cancer death rates by smoking status: comparison of the Three-Prefecture Cohort study in Japan to the Cancer Prevention Study II in the USA.
    Cancer Sci, 96(2): 120-6. [Abstract] [Full-text]
96. Reduced expression of Dicer associated with poor prognosis in lung cancer patients.
    Cancer Sci, 96(2): 111-5. [Abstract] [Full-text]
97. Throwing new light on lung cancer pathogenesis: updates on three recent topics.
    Cancer Sci, 96(2): 63-8. [Abstract] [Full-text]
98. The importance of chemotherapy dose intensity in lung cancer.
    Semin Oncol, 31(6): 25-31. [Abstract] [Full-text]
99. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
    Semin Oncol, 31(6): 25-33. [Abstract] [Full-text]
100. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
     Semin Oncol, 31(6): 52-8. [Abstract] [Full-text]
101. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
     Semin Oncol, 31(6): 47-51. [Abstract] [Full-text]
102. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
     Semin Oncol, 31(6): 42-6. [Abstract] [Full-text]
103. Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study.
     Br J Cancer, 92(4): 673-80. [Abstract] [Full-text]
104. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
     Br J Cancer, 92(4): 681-9. [Abstract] [Full-text]
105. Detection of oncogenic virus genomes and gene products in lung carcinoma.
     Br J Cancer, 92(4): 743-6. [Abstract] [Full-text]
106. SPLUNC1 (PLUNC) is expressed in glandular tissues of the respiratory tract and in lung tumours with a glandular phenotype.
     J Pathol, 205(4): 491-7. [Abstract] [Full-text]
107. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.
     Br J Cancer, 92(4): 775-83. [Abstract] [Full-text]
108. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
     Cancer, 103(5): 994-9. [Abstract] [Full-text]
109. Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
     Int J Clin Oncol, 10(1): 63-8. [Abstract] [Full-text]
110. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
     N Engl J Med, 352(8): 786-92. [Abstract] [Full-text]
111. Osteogenic pulmonary metastases originating from a phyllodes tumour of the breast with osteosarcomatous differentiation.
     Australas Radiol, 49(1): 63-5. [Abstract] [Full-text]
112. Trichoptysis caused by intrapulmonary teratoma: computed tomography and magnetic resonance imaging findings.
     Australas Radiol, 49(1): 53-6. [Abstract] [Full-text]
113. Comparison of relative forced expiratory volume of one second with dynamic magnetic resonance imaging parameters in healthy subjects and patients with lung cancer.
     J Magn Reson Imaging, 21(3): 212-8. [Abstract] [Full-text]
114. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
     Oncogene, 24(9): 1625-33. [Abstract] [Full-text]
115. Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis.
     Carcinogenesis, 26(3): 525-30. [Abstract] [Full-text]
116. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk.
     Int J Cancer, 114(5): 730-7. [Abstract] [Full-text]
117. Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E.
     Carcinogenesis, 26(3): 605-12. [Abstract] [Full-text]
118. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer.
     Carcinogenesis, 26(3): 649-56. [Abstract] [Full-text]
119. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
     Carcinogenesis, 26(3): 597-604. [Abstract] [Full-text]
120. Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.
     Support Care Cancer, 12(11): 767-73. [Abstract] [Full-text]
121. Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
     J Neurooncol, 71(3): 277-80. [Abstract] [Full-text]
122. Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
     J Neurooncol, 71(3): 259-65. [Abstract] [Full-text]
123. T cell response to Hu-D peptides in patients with anti-Hu syndrome.
     J Neurooncol, 71(3): 231-6. [Abstract] [Full-text]
124. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.
     J Clin Oncol, 23(7): 1538-47. [Abstract] [Full-text]
125. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
     J Clin Oncol, 23(7): 1530-7. [Abstract] [Full-text]
126. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
     Cancer Res, 65(4): 1598-605. [Abstract] [Full-text]
127. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
     Cancer Res, 65(4): 1541-6. [Abstract] [Full-text]
128. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
     Cancer Res, 65(4): 1479-88. [Abstract] [Full-text]
129. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
     Cancer Res, 65(4): 1459-70. [Abstract] [Full-text]
130. Susceptibility to aflatoxin B1-induced carcinogenesis correlates with tissue-specific differences in DNA repair activity in mouse and in rat.
     Cancer Res, 65(4): 1265-70. [Abstract] [Full-text]
131. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.
     Cancer Res, 65(4): 1207-12. [Abstract] [Full-text]
132. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 491-6. [Abstract] [Full-text]
133. Dietary patterns associated with male lung cancer risk in the Netherlands Cohort Study.
     Cancer Epidemiol Biomarkers Prev, 14(2): 483-90. [Abstract] [Full-text]
134. Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck.
     Cancer Detect Prev, 29(1): 59-65. [Abstract] [Full-text]
135. Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma.
     Respir Med, 99(3): 308-12. [Abstract] [Full-text]
136. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
     Respir Med, 99(3): 298-307. [Abstract] [Full-text]
137. Fluoroscopy-guided barium marking for localizing small pulmonary lesions before video-assisted thoracic surgery.
     Respir Med, 99(3): 285-9. [Abstract] [Full-text]
138. Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
     Int J Urol, 12(2): 208-10. [Abstract] [Full-text]
139. Pulmonary metastases: effect of CT section thickness on measurement--initial experience.
     Radiology, 234(3): 934-9. [Abstract] [Full-text]
140. Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience.
     Radiology, 234(3): 917-22. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.